Raj Wadwa
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 116 | 2023 | 3220 | 8.890 |
Why?
| Insulin Infusion Systems | 38 | 2023 | 289 | 4.390 |
Why?
| Blood Glucose | 59 | 2023 | 1894 | 3.500 |
Why?
| Insulin | 43 | 2023 | 2147 | 3.160 |
Why?
| Blood Glucose Self-Monitoring | 35 | 2023 | 461 | 3.000 |
Why?
| Hypoglycemic Agents | 41 | 2023 | 1020 | 2.880 |
Why?
| Hypoglycemia | 23 | 2022 | 382 | 2.280 |
Why?
| Pancreas, Artificial | 16 | 2021 | 65 | 2.280 |
Why?
| Diabetic Angiopathies | 16 | 2019 | 275 | 1.890 |
Why?
| Vascular Stiffness | 14 | 2019 | 396 | 1.860 |
Why?
| Cardiovascular Diseases | 25 | 2019 | 1729 | 1.790 |
Why?
| Glycated Hemoglobin A | 23 | 2022 | 742 | 1.680 |
Why?
| Adolescent | 92 | 2022 | 18785 | 1.410 |
Why?
| Telemedicine | 3 | 2022 | 581 | 1.170 |
Why?
| Child | 69 | 2023 | 18484 | 1.120 |
Why?
| Diabetes Mellitus, Type 2 | 11 | 2020 | 2006 | 1.080 |
Why?
| Albuminuria | 4 | 2019 | 188 | 1.070 |
Why?
| Young Adult | 51 | 2022 | 10940 | 0.940 |
Why?
| Dyslipidemias | 4 | 2019 | 156 | 0.870 |
Why?
| Humans | 130 | 2023 | 116836 | 0.800 |
Why?
| Biosensing Techniques | 2 | 2020 | 109 | 0.800 |
Why?
| Hyperglycemia | 10 | 2022 | 331 | 0.790 |
Why?
| Male | 91 | 2022 | 60330 | 0.750 |
Why?
| Uromodulin | 1 | 2019 | 26 | 0.750 |
Why?
| Female | 93 | 2022 | 63125 | 0.740 |
Why?
| Glycopeptides | 1 | 2019 | 64 | 0.730 |
Why?
| Carotid Intima-Media Thickness | 3 | 2018 | 62 | 0.670 |
Why?
| Insulin Lispro | 4 | 2022 | 36 | 0.660 |
Why?
| Ketones | 2 | 2016 | 46 | 0.630 |
Why?
| Biomarkers | 10 | 2020 | 3567 | 0.620 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 407 | 0.590 |
Why?
| Autonomic Nervous System | 3 | 2013 | 72 | 0.580 |
Why?
| Cholesterol | 6 | 2020 | 389 | 0.560 |
Why?
| Remote Consultation | 1 | 2015 | 41 | 0.550 |
Why?
| Diabetic Nephropathies | 5 | 2019 | 280 | 0.540 |
Why?
| Patient Compliance | 2 | 2015 | 593 | 0.510 |
Why?
| Adult | 51 | 2022 | 32062 | 0.480 |
Why?
| Monitoring, Ambulatory | 4 | 2020 | 94 | 0.480 |
Why?
| Cystatin C | 2 | 2015 | 70 | 0.470 |
Why?
| Diagnostic Techniques, Cardiovascular | 2 | 2014 | 17 | 0.470 |
Why?
| Child, Preschool | 16 | 2023 | 9698 | 0.470 |
Why?
| Calcinosis | 4 | 2014 | 300 | 0.460 |
Why?
| Patient Education as Topic | 4 | 2019 | 724 | 0.460 |
Why?
| Glucagon | 3 | 2016 | 95 | 0.440 |
Why?
| Case-Control Studies | 13 | 2020 | 3274 | 0.440 |
Why?
| Risk Factors | 27 | 2019 | 9077 | 0.430 |
Why?
| Triglycerides | 9 | 2022 | 550 | 0.420 |
Why?
| Insulin Aspart | 3 | 2022 | 25 | 0.420 |
Why?
| Arteries | 2 | 2010 | 247 | 0.420 |
Why?
| Diabetic Ketoacidosis | 5 | 2022 | 164 | 0.420 |
Why?
| Algorithms | 11 | 2022 | 1527 | 0.410 |
Why?
| Quality of Life | 5 | 2022 | 2299 | 0.400 |
Why?
| Graves Disease | 1 | 2010 | 33 | 0.400 |
Why?
| Friedreich Ataxia | 1 | 2010 | 63 | 0.370 |
Why?
| Adipose Tissue | 3 | 2022 | 680 | 0.370 |
Why?
| Glomerular Filtration Rate | 4 | 2019 | 598 | 0.360 |
Why?
| Cholesterol, LDL | 4 | 2014 | 320 | 0.360 |
Why?
| Diabetes Complications | 2 | 2007 | 228 | 0.340 |
Why?
| Pulse Wave Analysis | 10 | 2019 | 184 | 0.340 |
Why?
| Vascular Diseases | 2 | 2013 | 235 | 0.340 |
Why?
| Psychometrics | 3 | 2021 | 684 | 0.340 |
Why?
| Skiing | 2 | 2019 | 41 | 0.340 |
Why?
| Hyperlipidemias | 2 | 2007 | 142 | 0.340 |
Why?
| Middle Aged | 31 | 2022 | 28646 | 0.330 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 1520 | 0.320 |
Why?
| Calibration | 4 | 2019 | 136 | 0.300 |
Why?
| Insulin Resistance | 6 | 2019 | 1171 | 0.300 |
Why?
| Receptors, Interleukin-2 | 1 | 2005 | 66 | 0.290 |
Why?
| Coronary Artery Disease | 3 | 2007 | 697 | 0.280 |
Why?
| Apolipoproteins B | 1 | 2014 | 56 | 0.270 |
Why?
| Self Report | 2 | 2020 | 692 | 0.270 |
Why?
| Reproducibility of Results | 8 | 2021 | 2910 | 0.270 |
Why?
| Exercise | 5 | 2019 | 1806 | 0.270 |
Why?
| Blood Pressure | 7 | 2014 | 1718 | 0.260 |
Why?
| Infusion Pumps, Implantable | 2 | 2020 | 20 | 0.260 |
Why?
| Heart Rate | 5 | 2019 | 807 | 0.250 |
Why?
| Adiponectin | 4 | 2012 | 212 | 0.250 |
Why?
| Pilot Projects | 2 | 2020 | 1436 | 0.250 |
Why?
| Body Mass Index | 10 | 2020 | 2063 | 0.250 |
Why?
| Kidney | 3 | 2022 | 1224 | 0.240 |
Why?
| Diabetic Neuropathies | 3 | 2019 | 96 | 0.230 |
Why?
| Blood Vessels | 2 | 2018 | 191 | 0.230 |
Why?
| Cholesterol, HDL | 4 | 2014 | 211 | 0.230 |
Why?
| Lipids | 3 | 2014 | 630 | 0.220 |
Why?
| Computer Systems | 2 | 2018 | 52 | 0.220 |
Why?
| Hypertension | 4 | 2019 | 1214 | 0.220 |
Why?
| Adiposity | 2 | 2018 | 507 | 0.220 |
Why?
| Technology | 1 | 2022 | 77 | 0.210 |
Why?
| Uric Acid | 2 | 2015 | 363 | 0.210 |
Why?
| Age Factors | 9 | 2016 | 3218 | 0.210 |
Why?
| Cohort Studies | 11 | 2017 | 5046 | 0.210 |
Why?
| Cross-Over Studies | 6 | 2019 | 496 | 0.210 |
Why?
| Glycosides | 1 | 2021 | 35 | 0.200 |
Why?
| Adolescent Behavior | 2 | 2017 | 493 | 0.200 |
Why?
| Guideline Adherence | 2 | 2015 | 543 | 0.200 |
Why?
| Self-Management | 1 | 2022 | 116 | 0.200 |
Why?
| Microvessels | 2 | 2018 | 76 | 0.200 |
Why?
| Sports | 2 | 2019 | 174 | 0.190 |
Why?
| Patient Dropouts | 1 | 2020 | 74 | 0.190 |
Why?
| Prevalence | 6 | 2014 | 2421 | 0.190 |
Why?
| Carotid Arteries | 2 | 2013 | 187 | 0.190 |
Why?
| Coronary Vessels | 2 | 2014 | 271 | 0.180 |
Why?
| Administration, Intranasal | 2 | 2016 | 89 | 0.180 |
Why?
| Brachial Artery | 3 | 2016 | 192 | 0.180 |
Why?
| Bacterial Vaccines | 1 | 1999 | 62 | 0.180 |
Why?
| Treatment Outcome | 11 | 2022 | 9285 | 0.180 |
Why?
| Evidence-Based Medicine | 2 | 2014 | 725 | 0.180 |
Why?
| Follow-Up Studies | 8 | 2019 | 4898 | 0.170 |
Why?
| Biomedical Technology | 1 | 2018 | 36 | 0.170 |
Why?
| Pneumococcal Infections | 1 | 1999 | 98 | 0.170 |
Why?
| Infant | 7 | 2019 | 8219 | 0.170 |
Why?
| Cardiotonic Agents | 1 | 2018 | 137 | 0.170 |
Why?
| Streptococcus pneumoniae | 1 | 1999 | 130 | 0.170 |
Why?
| Antihypertensive Agents | 3 | 2014 | 461 | 0.170 |
Why?
| Insulin, Regular, Human | 3 | 2022 | 25 | 0.170 |
Why?
| Endocrinology | 1 | 2018 | 69 | 0.170 |
Why?
| Transplantation Conditioning | 1 | 2019 | 179 | 0.170 |
Why?
| Ohio | 5 | 2015 | 136 | 0.170 |
Why?
| Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 17 | 0.160 |
Why?
| Diabetic Cardiomyopathies | 2 | 2016 | 38 | 0.160 |
Why?
| Proprotein Convertase 9 | 1 | 2017 | 43 | 0.160 |
Why?
| Cross-Sectional Studies | 7 | 2017 | 4572 | 0.150 |
Why?
| Sex Factors | 5 | 2016 | 1931 | 0.150 |
Why?
| Immunization | 1 | 1999 | 408 | 0.150 |
Why?
| Regression Analysis | 4 | 2014 | 1109 | 0.150 |
Why?
| Risk Assessment | 4 | 2014 | 3159 | 0.150 |
Why?
| Pediatric Obesity | 2 | 2019 | 415 | 0.150 |
Why?
| Aorta | 1 | 2018 | 413 | 0.150 |
Why?
| Wyoming | 1 | 2015 | 20 | 0.150 |
Why?
| Perception | 1 | 2018 | 313 | 0.140 |
Why?
| Periodontal Diseases | 1 | 2015 | 78 | 0.140 |
Why?
| Surveys and Questionnaires | 7 | 2021 | 4803 | 0.140 |
Why?
| Metformin | 1 | 2018 | 286 | 0.140 |
Why?
| Videoconferencing | 1 | 2015 | 60 | 0.140 |
Why?
| Lipoproteins | 2 | 2022 | 173 | 0.140 |
Why?
| Hormones | 1 | 2015 | 138 | 0.140 |
Why?
| Aged | 11 | 2022 | 20173 | 0.140 |
Why?
| Consensus | 3 | 2023 | 500 | 0.140 |
Why?
| Delivery of Health Care | 1 | 2022 | 782 | 0.140 |
Why?
| Inflammation | 2 | 2018 | 2505 | 0.140 |
Why?
| Coronary Disease | 3 | 2007 | 434 | 0.140 |
Why?
| Colorado | 9 | 2017 | 4451 | 0.140 |
Why?
| Atherosclerosis | 3 | 2015 | 314 | 0.130 |
Why?
| Self Care | 2 | 2014 | 349 | 0.130 |
Why?
| Pandemics | 1 | 2022 | 1112 | 0.130 |
Why?
| Patient Satisfaction | 1 | 2018 | 613 | 0.130 |
Why?
| Vascular Calcification | 1 | 2016 | 125 | 0.130 |
Why?
| Ketosis | 1 | 2014 | 14 | 0.130 |
Why?
| Dietary Fiber | 1 | 2014 | 44 | 0.130 |
Why?
| Creatinine | 2 | 2015 | 467 | 0.130 |
Why?
| Parents | 4 | 2022 | 1158 | 0.130 |
Why?
| Goals | 1 | 2015 | 149 | 0.120 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 567 | 0.120 |
Why?
| Circadian Rhythm | 2 | 2015 | 452 | 0.120 |
Why?
| Sleep | 2 | 2022 | 758 | 0.120 |
Why?
| Bionics | 2 | 2022 | 8 | 0.120 |
Why?
| Monitoring, Physiologic | 1 | 2015 | 267 | 0.120 |
Why?
| Pediatrics | 2 | 2018 | 1026 | 0.120 |
Why?
| Prognosis | 6 | 2020 | 3506 | 0.120 |
Why?
| Registries | 3 | 2020 | 1919 | 0.110 |
Why?
| Acetaminophen | 1 | 2015 | 249 | 0.110 |
Why?
| Longitudinal Studies | 6 | 2016 | 2660 | 0.110 |
Why?
| Femoral Artery | 1 | 2013 | 171 | 0.110 |
Why?
| Obesity | 3 | 2020 | 2685 | 0.110 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 159 | 0.110 |
Why?
| Kidney Function Tests | 1 | 2011 | 158 | 0.110 |
Why?
| Precision Medicine | 1 | 2014 | 295 | 0.110 |
Why?
| Thyroidectomy | 1 | 2010 | 47 | 0.100 |
Why?
| Infant, Newborn | 4 | 2019 | 5168 | 0.100 |
Why?
| Injections, Subcutaneous | 2 | 2020 | 155 | 0.100 |
Why?
| Outpatients | 3 | 2021 | 286 | 0.100 |
Why?
| Vitamin D | 1 | 2013 | 349 | 0.100 |
Why?
| Hypolipidemic Agents | 2 | 2008 | 93 | 0.100 |
Why?
| Glycosuria | 1 | 2009 | 9 | 0.100 |
Why?
| United States | 8 | 2020 | 12641 | 0.100 |
Why?
| Blood Flow Velocity | 2 | 2010 | 380 | 0.090 |
Why?
| Diabetes Mellitus | 3 | 2018 | 942 | 0.090 |
Why?
| Double-Blind Method | 3 | 2021 | 1704 | 0.090 |
Why?
| Meals | 2 | 2019 | 65 | 0.090 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 8 | 0.080 |
Why?
| Combined Modality Therapy | 3 | 2017 | 1194 | 0.080 |
Why?
| Life Style | 2 | 2008 | 411 | 0.080 |
Why?
| Mobile Applications | 2 | 2020 | 143 | 0.080 |
Why?
| Cold Temperature | 2 | 2019 | 152 | 0.080 |
Why?
| Age Distribution | 2 | 2006 | 391 | 0.080 |
Why?
| Radionuclide Imaging | 1 | 2007 | 139 | 0.080 |
Why?
| Equipment Design | 2 | 2019 | 533 | 0.080 |
Why?
| Health Promotion | 1 | 2014 | 682 | 0.080 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 1006 | 0.080 |
Why?
| Fetal Distress | 1 | 2006 | 13 | 0.080 |
Why?
| Disease Progression | 5 | 2018 | 2522 | 0.080 |
Why?
| Catheter Ablation | 1 | 2010 | 336 | 0.080 |
Why?
| Apolipoproteins A | 1 | 2006 | 19 | 0.080 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 84 | 0.080 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 71 | 0.070 |
Why?
| Polymorphism, Genetic | 2 | 2007 | 648 | 0.070 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 231 | 0.070 |
Why?
| Hypertrophy | 2 | 2016 | 124 | 0.070 |
Why?
| Seasons | 2 | 2019 | 433 | 0.070 |
Why?
| Postprandial Period | 2 | 2018 | 110 | 0.070 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1399 | 0.070 |
Why?
| Family Health | 1 | 2006 | 190 | 0.070 |
Why?
| Time Factors | 3 | 2014 | 6916 | 0.070 |
Why?
| Smoking | 1 | 2014 | 1642 | 0.070 |
Why?
| Pregnancy in Diabetics | 1 | 2006 | 89 | 0.070 |
Why?
| Infant, Newborn, Diseases | 1 | 2006 | 105 | 0.070 |
Why?
| Linear Models | 3 | 2014 | 874 | 0.070 |
Why?
| Feasibility Studies | 2 | 2018 | 757 | 0.070 |
Why?
| Radiography | 1 | 2007 | 854 | 0.070 |
Why?
| Hair | 1 | 2004 | 67 | 0.070 |
Why?
| Cotinine | 1 | 2004 | 73 | 0.070 |
Why?
| Glucose Intolerance | 1 | 2005 | 138 | 0.060 |
Why?
| Sex Distribution | 1 | 2005 | 390 | 0.060 |
Why?
| Prospective Studies | 3 | 2022 | 6429 | 0.060 |
Why?
| Stroke | 1 | 2012 | 989 | 0.060 |
Why?
| Seizures | 1 | 2006 | 340 | 0.060 |
Why?
| Chitinase-3-Like Protein 1 | 1 | 2022 | 18 | 0.060 |
Why?
| Hemodynamics | 2 | 2022 | 1096 | 0.060 |
Why?
| Glucose | 2 | 2021 | 923 | 0.060 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 370 | 0.060 |
Why?
| Incidence | 3 | 2014 | 2477 | 0.060 |
Why?
| Inflammation Mediators | 1 | 2006 | 527 | 0.060 |
Why?
| Rats | 1 | 2012 | 6091 | 0.060 |
Why?
| Predictive Value of Tests | 3 | 2015 | 1972 | 0.060 |
Why?
| Societies, Medical | 2 | 2018 | 736 | 0.060 |
Why?
| Reference Values | 2 | 2018 | 844 | 0.050 |
Why?
| Tobacco Smoke Pollution | 1 | 2004 | 236 | 0.050 |
Why?
| Insulin-Secreting Cells | 1 | 2005 | 319 | 0.050 |
Why?
| Sitosterols | 1 | 2020 | 1 | 0.050 |
Why?
| Phytosterols | 1 | 2020 | 11 | 0.050 |
Why?
| Motor Activity | 2 | 2018 | 744 | 0.050 |
Why?
| Environmental Exposure | 1 | 2004 | 394 | 0.050 |
Why?
| Intention to Treat Analysis | 1 | 2020 | 69 | 0.050 |
Why?
| Social Conditions | 1 | 2019 | 12 | 0.050 |
Why?
| Pancreas | 1 | 2022 | 273 | 0.050 |
Why?
| Logistic Models | 1 | 2005 | 1999 | 0.050 |
Why?
| India | 1 | 2020 | 125 | 0.050 |
Why?
| Retrospective Studies | 5 | 2014 | 12102 | 0.050 |
Why?
| Autonomic Nervous System Diseases | 1 | 2019 | 28 | 0.050 |
Why?
| Factor Analysis, Statistical | 1 | 2020 | 293 | 0.050 |
Why?
| Vaccines, Conjugate | 1 | 1999 | 57 | 0.050 |
Why?
| Fear | 1 | 2022 | 344 | 0.050 |
Why?
| Personal Satisfaction | 1 | 2021 | 182 | 0.050 |
Why?
| Anthropometry | 1 | 2019 | 215 | 0.050 |
Why?
| Smartphone | 1 | 2019 | 63 | 0.040 |
Why?
| Waist Circumference | 1 | 2018 | 127 | 0.040 |
Why?
| International Cooperation | 1 | 2018 | 176 | 0.040 |
Why?
| Virginia | 1 | 2017 | 50 | 0.040 |
Why?
| Accelerometry | 1 | 2018 | 75 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 1008 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 202 | 0.040 |
Why?
| Sex Characteristics | 2 | 2017 | 682 | 0.040 |
Why?
| Age of Onset | 1 | 2018 | 472 | 0.040 |
Why?
| Ambulatory Care Facilities | 1 | 2019 | 228 | 0.040 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 100 | 0.040 |
Why?
| Vascular Capacitance | 1 | 2016 | 4 | 0.040 |
Why?
| Magnetic Resonance Angiography | 1 | 2018 | 241 | 0.040 |
Why?
| Family | 1 | 2020 | 571 | 0.040 |
Why?
| Powders | 1 | 2016 | 35 | 0.040 |
Why?
| Mass Spectrometry | 1 | 2019 | 692 | 0.040 |
Why?
| Injections, Intramuscular | 1 | 2016 | 121 | 0.040 |
Why?
| Food Preferences | 1 | 2017 | 132 | 0.040 |
Why?
| Nausea | 1 | 2016 | 111 | 0.040 |
Why?
| Equipment Failure | 1 | 2016 | 125 | 0.040 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 3211 | 0.040 |
Why?
| Ankle Brachial Index | 1 | 2015 | 29 | 0.040 |
Why?
| Drug Delivery Systems | 1 | 2018 | 328 | 0.030 |
Why?
| International Agencies | 1 | 2014 | 34 | 0.030 |
Why?
| Child Behavior | 1 | 2017 | 245 | 0.030 |
Why?
| Apolipoproteins | 1 | 2014 | 40 | 0.030 |
Why?
| Early Diagnosis | 1 | 2016 | 252 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2015 | 184 | 0.030 |
Why?
| Societies, Scientific | 1 | 2014 | 53 | 0.030 |
Why?
| Adolescent Medicine | 1 | 2014 | 34 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2015 | 550 | 0.030 |
Why?
| Program Evaluation | 1 | 2019 | 862 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2017 | 379 | 0.030 |
Why?
| Patient Care Team | 1 | 2019 | 522 | 0.030 |
Why?
| Nutrition Policy | 1 | 2014 | 60 | 0.030 |
Why?
| China | 1 | 2014 | 242 | 0.030 |
Why?
| Pressure | 1 | 2014 | 265 | 0.030 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 230 | 0.030 |
Why?
| Feeding Behavior | 1 | 2018 | 551 | 0.030 |
Why?
| Fibrinogen | 1 | 2014 | 155 | 0.030 |
Why?
| Diabetic Retinopathy | 1 | 2014 | 137 | 0.030 |
Why?
| Risk | 1 | 2016 | 942 | 0.030 |
Why?
| Primary Prevention | 1 | 2015 | 221 | 0.030 |
Why?
| American Heart Association | 1 | 2014 | 299 | 0.030 |
Why?
| Up-Regulation | 1 | 2015 | 924 | 0.030 |
Why?
| Quality Improvement | 1 | 2019 | 932 | 0.030 |
Why?
| Genotype | 2 | 2007 | 1838 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 2149 | 0.030 |
Why?
| Pulsatile Flow | 1 | 2010 | 58 | 0.020 |
Why?
| Animals | 1 | 2012 | 34530 | 0.020 |
Why?
| Practice Patterns, Physicians' | 1 | 2018 | 1220 | 0.020 |
Why?
| Arm | 1 | 2010 | 93 | 0.020 |
Why?
| Elasticity | 1 | 2010 | 199 | 0.020 |
Why?
| South Carolina | 1 | 2008 | 34 | 0.020 |
Why?
| Lipoproteins, HDL | 1 | 2008 | 84 | 0.020 |
Why?
| Nutrition Therapy | 1 | 2008 | 33 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2008 | 150 | 0.020 |
Why?
| Leg | 1 | 2010 | 261 | 0.020 |
Why?
| Models, Biological | 1 | 2015 | 1793 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 11 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 23 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 50 | 0.020 |
Why?
| Pancreatic Function Tests | 1 | 2005 | 4 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2006 | 283 | 0.020 |
Why?
| C-Peptide | 1 | 2005 | 130 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2445 | 0.020 |
Why?
| Glucose Tolerance Test | 1 | 2005 | 370 | 0.020 |
Why?
| Mother-Child Relations | 1 | 2004 | 127 | 0.020 |
Why?
| Population Surveillance | 1 | 2006 | 444 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2008 | 960 | 0.010 |
Why?
| Oxidative Stress | 1 | 2006 | 1240 | 0.010 |
Why?
| DNA | 1 | 2006 | 1369 | 0.010 |
Why?
| Pregnancy | 1 | 2006 | 5480 | 0.010 |
Why?
|
|
Wadwa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|